Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alexion Snags 2nd FDA Voucher On Kanuma Win

This article was originally published in Scrip

Executive Summary

The FDA's approval on Dec. 8 of Alexion Pharmaceuticals Inc.'s enzyme replacement therapy (ERT) Kanuma (sebelipase alfa) was significant for several reasons – mostly, because it provides patients with the first treatment in the US for a deadly, progressive ultra-rare genetic disease, known as lysosomal acid lipase deficiency (LAL-D), which causes multi-organ damage, resulting in premature death.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register